The H2 receptor antagonist nizatidine is a p-glycoprotein substrate: Characterization of its intestinal epithelial cell efflux transport

AAPS Journal

Volumn 11, Issue 2, 2009, Pages 205-213

  Dahan, Arik ^a   Sabit, Hairat ^a   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

BCS class III drugs; Caco 2 permeability; Efflux transporters; Intestinal absorption; Nizatidine; P glycoprotein

Indexed keywords

4 AMINOHIPPURIC ACID; CYCLOSPORIN A; ERYTHROMYCIN; FUMITREMORGIN C; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; INDOMETACIN; KETOCONAZOLE; NIZATIDINE; PROBENECID; QUINIDINE; VERAPAMIL; VERLUKAST; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CALCIUM CHANNEL BLOCKING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; TUMOR PROTEIN;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; INTESTINE ABSORPTION; INTESTINE EPITHELIUM CELL; STOMACH SECRETION; ACTIVE TRANSPORT; ALGORITHM; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; EPITHELIUM CELL; FOOD DRUG INTERACTION; INTESTINE; KINETICS; METABOLISM; ULTRAVIOLET SPECTROPHOTOMETRY;

ALGORITHMS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPITHELIAL CELLS; FOOD-DRUG INTERACTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; INTESTINES; KINETICS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NIZATIDINE; P-GLYCOPROTEIN; SPECTROPHOTOMETRY, ULTRAVIOLET; VERAPAMIL;

EID: 68049095727     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9092-5     Document Type: Article

References (54)

1. S. R. Orenstein, D. A. Gremse, C. D. Pantaleon, D. F. Kling, and K. S. Rotenberg. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: An open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin. Ther. 27:472 (2005).
2. M. Sasaki, T. Sudoh, and A. Fujimura. Pharmacokinetics of ranitidine and nizatidine in very elderly patients. Am. J. Ther. 12:223-225 (2005).
3. M. Feldman, and M. Burton. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. 2. N. Engl. J. Med. 323:1749-1755 (1990).
4. M. Feldman, and M. Burton. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. 1. N. Engl. J. Med. 323:1672-1680 (1990).
5. M. P. Knadler, R. F. Bergstrom, J. T. Callaghan, and A. Rubin. Nizatidine, an H2-blocker. Its metabolism and disposition in man. Drug Metab. Dispos. 14:175-182 (1986).
6. L. Z. Benet, T. Izumi, Y. Zhang, J. A. Silverman, and V. J. Wacher. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control Release. 62:25 (1999).
7. V. J. Wacher, J. A. Silverman, Y. Zhang, and L. Z. Benet. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87:1322-1330 (1998).
8. R. Garcia del Moral, F. O'Valle, M. Andujar, M. Aguilar, M. A. Lucena, J. Lopez-Hidalgo, C. Ramirez, M. T. Medina-Cano, D. Aguilar, and M. Gomez-Morales. Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study. Am. J. Pathol. 146:398-408 (1995).
9. M. Ceckova-Novotna, P. Pavek, and F. Staud. P-glycoprotein in the placenta: Expression, localization, regulation and function. Reprod. Toxicol. 22:400 (2006).
10. A. Takano, H. Kusuhara, T. Suhara, I. Ieiri, T. Morimoto, Y. J. Lee, J. Maeda, Y. Ikoma, H. Ito, K. Suzuki, and Y. Sugiyama. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J. Nucl. Med. 47:1427-1433 (2006).
11. M. F. Fromm. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25:423 (2004).
12. L. Z. Benet, C. L. Cummins, and C. Y. Wu. Transporter-enzyme interactions: Implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4:393-398 (2003).
13. L. Z. Benet, C. L. Cummins, and C. Y. Wu. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277:3 (2004).
14. A. Dahan, and H. Altman. Food-drug interaction: Grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur. J. Clin. Nutr. 58:1-9 (2004).
15. J. H. Lin. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 55:53 (2003).
16. M. Takano, R. Yumoto, and T. Murakami. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 109:137 (2006).
17. D. Bourdet, and D. Thakker. Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: Role of pH-dependent organic cation uptake system and P-glycoprotein. Pharm. Res. 23:1165 (2006).
18. A. Collett, N. B. Higgs, E. Sims, M. Rowland, and A. G. Warhurst. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. 288:171-178 (1999).
19. A. Dahan, and G. L. Amidon. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: The role of efflux transport in the oral absorption of BCS class III drugs. Mol. Pharmaceutics. 6:19-28 (2008).
20. K. Lee, C. Ng, K. L. R. Brouwer, and D. R. Thakker. Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 303:574-580 (2002).
21. J. Gao, O. Murase, R. L. Schowen, J. Aube, and R. T. Borchardt. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm. Res. 18:171 (2001).
22. A. Dahan, and G. L. Amidon. Grapefruit juice and its constituents augment colchicine intestinal absorption: Potential hazardous interaction and the role of P-glycoprotein. Pharm. Res. 26:883-892 (2009).
23. J. H. Chang, and L. Z. Benet. Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. Mol. Pharmaceutics. 2:428-434 (2005).
24. M. Rodriguez-Ibanez, R. Nalda-Molina, M. Montalar-Montero, M. V. Bermejo, V. Merino, and T. M. Garrigues. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: In vitro and in situ inhibition studies. Eur. J. Pharm. Biopharm. 55:241 (2003).
25. M. P. Draper, R. L. Martell, and S. B. Levy. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer. 75:810-815 (1997).
26. R. Evers, G. Zaman, L. van Deemter, H. Jansen, J. Calafat, L. Oomen, R. Oude Elferink, P. Borst, and A. Schinkel. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 97:1211-1218 (1996).
27. N. Petri, C. Tannergren, D. Rungstad, and H. Lennernas. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. 21:1398 (2004).
28. Y. Ji, and M. E. Morris. Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein). Mol. Pharmaceutics. 2:414-419 (2005).
29. H. Nakamura, H. Sano, M. Yamazaki, and Y. Sugiyama. Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: Contribution of type I system. J. Pharmacol. Exp. Ther. 269:1220-1227 (1994).
30. S. M. Abdel-Rahman, F. K. Johnson, G. Gauthier-Dubois, I. E. Weston, and G. L. Kearns. The bioequivalence of nizatidine (Axid(R)) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule. J. Clin. Pharmacol. 43:148-153 (2003).
31. P. H. Howard, and W. M. Meylan. Handbook of physical properties of organic chemicals, CRC, New York, 1996.
32. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413 (1995).
33. N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernas, A. S. Hussain, H. E. Junginger, S. A. Stavchansky, K. K. Midha, V. P. Shah, and G. L. Amidon. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharmaceutics. 1:85-96 (2004).
34. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L. X. Yu, and G. L. Amidon. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol. Pharmaceutics. 3:631-643 (2006).
35. S. Berggren, J. Hoogstraate, U. Fagerholm, and H. Lennernas. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur. J. Pharm. Sci. 21:553 (2004).
36. W. Chiou, S. Chung, T. Wu, and C. Ma. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39:93-101 (2001).
37. W. L. Chiou, S. M. Chung, and T. C. Wu. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm. Res. 17:205 (2000).
38. Y. J. Lee, S. J. Chung, and C. K. Shim. Limited role of P-glycoprotein in the intestinal absorption of cyclosporin A. Biol. Pharm. Bull. 28:760 (2005).
39. J. Lin. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today. 40:5-22 (2004).
40. H. Toyobuku, I. Tamai, K. Ueno, and A. Tsuji. Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J. Pharm. Sci. 92:2249-2259 (2003).
41. R. H. Stephens, J. Tanianis-Hughes, N. B. Higgs, M. Humphrey, and G. Warhurst. Region-dependent modulation of intestinal permeability by drug efflux transporters: In vitro studies in mdr1a(-/-) mouse intestine. J. Pharmacol. Exp. Ther. 303:1095-1101 (2002).
42. S. Tamura, A. Ohike, R. Ibuki, G. L. Amidon, and S. Yamashita. Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci. 91:719-729 (2002).
43. J. M. M. Terwogt, J. H. Beijnen, W. W. t. B. Huinink, H. Rosing, and J. H. M. Schellens. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet. 352:285 (1998).
44. X. Cao, L. X. Yu, C. Barbaciru, C. P. Landowski, H. C. Shin, S. Gibbs, H. A. Miller, G. L. Amidon, and D. Sun. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol. Pharmaceutics. 2: 329-340 (2005).
45. I. Gonzalez-Alvarez, C. Fernandez-Teruel, V. G. Casabo-Alos, T. M. Garrigues, J. E. Polli, A. Ruiz-Garcia, and M. Bermejo. In situ kinetic modelling of intestinal efflux in rats: Functional characterization of segmental differences and correlation with in vitro results. Biopharm. Drug Dispos. 28:229-239 (2007).
46. C. P. Landowski, D. Sun, D. R. Foster, S. S. Menon, J. L. Barnett, L. S. Welage, C. Ramachandran, and G. L. Amidon. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J. Pharmacol. Exp. Ther. 306:778-786 (2003).
47. D. Tam, R. G. Tirona, and K. S. Pang. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab. Dispos. 31:373-383 (2003).
48. B. Valenzuela, A. Nacher, P. Ruiz-Carretero, A. Martin-Villodre, G. Lopez-Carballo, and D. Barettino. Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J. Pharm. Sci. 93:1641-1648 (2004).
49. A. Dahan, R. Duvdevani, E. Dvir, A. Elmann, and A. Hoffman. A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: In-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J. Control Release. 119:86 (2007).
50. A. Hoffman. Pharmacodynamic aspects of sustained release preparations. Adv. Drug Deliv. Rev. 33:185 (1998).
51. R. Lobenberg, J. S. Kim, and G. L. Amidon. Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur. J. Pharm. Biopharm. 60:17 (2005).
52. M. Tubic, D. Wagner, H. Spahn-Langguth, C. Weiler, R. Wanitschke, W. O. Bocher, and P. Langguth. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. Eur. J. Pharm. Sci. 29:231 (2006).
53. R. A. Blum, A. J. Braverman, P. Rice, and F. K. Johnson. Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects. J. Clin. Pharmacol. 43:74-83 (2003).
54. J. T. Callaghan, R. F. Bergstrom, A. Rubin, S. Chernish, R. Crabtree, M. P. Knadler, B. Obermeyer, W. W. Offen, D. W. Schneck, G. Aronoff, and K. C. Lasseter. A pharmacokinetic profile of nizatidine in man. Scand. J. Gastroenterol. 22:9-17 (1987).